Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Caimi, PF; Ai, WY; Alderuccio, JP; Ardeshna, KM; Hamadani, M; Hess, B; Kahl, BS; Radford, J; Solh, M; Stathis, A; Zinzani, PL; Havenith, K; Feingold, J; He, S; Qin, YJ; Ungar, D; Zhang, XY; Carlo-Stella, C

Caimi, PF (corresponding author), Case Western Reserve Univ, Univ Hosp Cleveland Med Ctr, Cleveland, OH 44106 USA.

LANCET ONCOLOGY, 2021; 22 (6): 790

Abstract

Background Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who do not respond to or who have progressive disease after salv......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索